Dacomitinib recommended as first-line treatment for NSCLC

Research has shown that dacomitinib significantly improves progression-free survival over gefitinib in EGFR-mutation-positive NSCLC.
Research has shown that dacomitinib significantly improves progression-free survival over gefitinib in EGFR-mutation-positive NSCLC.